m+Medelevator.RU
← Поиск публикаций
American journal of obstetrics and gynecology · 2026

Management of multiple sclerosis during pregnancy and the reproductive years in 2026: an expert clinical review.

СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Balshi Alexandra, Dobson Ruth, Houtchens Maria, McConville Kylie, McElrath Thomas F, Sadovnick A Dessa, Tesfalul Martha, Hellwig Kerstin, Bove Riley

Аннотация

Women's neurology and obstetrics/gynecology experts convened to consolidate the best available evidence on multiple sclerosis management in reproductive-aged women, especially regarding the use of multiple sclerosis disease-modifying therapies surrounding pregnancy and lactation. To update 2014 clinical recommendations, an expert clinical review informed by a systematic literature search of PubMed, LactMed, and ClinicalTrials.gov was conducted utilizing keywords "multiple sclerosis" and "pregnancy." A total of 774 papers were screened for inclusion. To provide updated guidelines, 2 reviewers prioritized studies according to strength of evidence and relevance to validating/updating our clinical management recommendations. To provide updated information about pregnancy and lactation safety of available multiple sclerosis disease-modifying therapies, an additional reviewer synthesized all available studies. All authors then reviewed data to craft consensus guidelines. We encourage collaborative care models to optimize symptom control, social support, and maternal wellbeing before, during, and after pregnancy. In most cases, multiple sclerosis is not associated with increased risks of adverse pregnancy outcomes, although some studies have reported slightly elevated risks of lower birthweight, preterm birth, and operative delivery. With appropriate monitoring, MS disease activity can often be minimized throughout the childbearing period by continuation or strategic timing of many disease-modifying therapies to optimize maternal disease control while minimizing fetal risk. The postpartum period represents a period of increased medical and psychological risk, and close follow-up is recommended. After childbearing is complete, gynecological care can shift to prevention and management of gynecological complications (disease-modifying therapy-associated infections and risk of cervical dysplasia) and of the menopausal transition.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты